Ou DL - Search Results

1

Lenalidomide as second-line therapy for advanced hepatocellular carcinoma: exploration of biomarkers for treatment efficacy.

Shao YY, Chen BB, Ou DL, Lin ZZ, Hsu CH, Wang MJ, Cheng AL, Hsu C. Shao YY, et al. Among authors: ou dl. Aliment Pharmacol Ther. 2017 Oct;46(8):722-730. doi: 10.1111/apt.14270. Epub 2017 Aug 17. Aliment Pharmacol Ther. 2017. PMID: 28815645 Clinical Trial.

2

Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma.

Shen YC, Ou DL, Hsu C, Lin KL, Chang CY, Lin CY, Liu SH, Cheng AL. Shen YC, et al. Among authors: ou dl. Br J Cancer. 2013 Jan 15;108(1):72-81. doi: 10.1038/bjc.2012.559. Epub 2012 Dec 20. Br J Cancer. 2013. PMID: 23257894 Free PMC article.

3

Chemokine receptor expression profiles in nasopharyngeal carcinoma and their association with metastasis and radiotherapy.

Ou DL, Chen CL, Lin SB, Hsu CH, Lin LI. Ou DL, et al. J Pathol. 2006 Nov;210(3):363-73. doi: 10.1002/path.2053. J Pathol. 2006. PMID: 16955398

4

CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia.

Lin TC, Hou HA, Chou WC, Ou DL, Yu SL, Tien HF, Lin LI. Lin TC, et al. Among authors: ou dl. Leukemia. 2011 Jan;25(1):32-40. doi: 10.1038/leu.2010.222. Epub 2010 Oct 7. Leukemia. 2011. PMID: 20927134

5

Regorafenib enhances M1/M2 macrophage polarization by inhibiting the secretion of plasminogen activator inhibitor-1 in head and neck squamous cell carcinoma.

Chen YH, Lee YM, Ou DL, Hsu CL, Hsu C, Chen CN, Ko JY, Tan CT. Chen YH, et al. Among authors: ou dl. Life Sci. 2024 Dec 1;358:123147. doi: 10.1016/j.lfs.2024.123147. Epub 2024 Oct 15. Life Sci. 2024. PMID: 39419267 Free article.

6

A potential novel cancer immunotherapy: Agonistic anti-CD40 antibodies.

Jian CZ, Lin L, Hsu CL, Chen YH, Hsu C, Tan CT, Ou DL. Jian CZ, et al. Among authors: ou dl. Drug Discov Today. 2024 Mar;29(3):103893. doi: 10.1016/j.drudis.2024.103893. Epub 2024 Jan 23. Drug Discov Today. 2024. PMID: 38272173 Review.

7

Nano-modified viruses prime the tumor microenvironment and promote the photodynamic virotherapy in liver cancer.

Ou DL, Liao ZX, Kempson IM, Li L, Yang PC, Tseng SJ. Ou DL, et al. J Biomed Sci. 2024 Jan 2;31(1):1. doi: 10.1186/s12929-023-00989-1. J Biomed Sci. 2024. PMID: 38163894 Free PMC article.

8

Anti-leukemia effects of omipalisib in acute myeloid leukemia: inhibition of PI3K/AKT/mTOR signaling and suppression of mitochondrial biogenesis.

Tseng CY, Fu YH, Ou DL, Lu JW, Hou HA, Lin LI. Tseng CY, et al. Among authors: ou dl. Cancer Gene Ther. 2023 Dec;30(12):1691-1701. doi: 10.1038/s41417-023-00675-2. Epub 2023 Oct 11. Cancer Gene Ther. 2023. PMID: 37821641

9

Genomic and Transcriptomic Landscape of an Oral Squamous Cell Carcinoma Mouse Model for Immunotherapy.

Lee YM, Hsu CL, Chen YH, Ou DL, Hsu C, Tan CT. Lee YM, et al. Among authors: ou dl. Cancer Immunol Res. 2023 Nov 1;11(11):1553-1567. doi: 10.1158/2326-6066.CIR-23-0133. Cancer Immunol Res. 2023. PMID: 37669022 Free PMC article.

10

SN-38, an active metabolite of irinotecan, enhances anti-PD-1 treatment efficacy in head and neck squamous cell carcinoma.

Lee YM, Chen YH, Ou DL, Hsu CL, Liu JH, Ko JY, Hu MC, Tan CT. Lee YM, et al. Among authors: ou dl. J Pathol. 2023 Apr;259(4):428-440. doi: 10.1002/path.6055. Epub 2023 Feb 24. J Pathol. 2023. PMID: 36641765

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

44 results

Search Page

Filters